retatrutide weight loss clinical trials retatrutide New GLP-1 obesity drug, retatrutide, shows added benefits Retatrutide Subcutaneous Fat Loss Results:

G.NiessenH

2016;7(S1):7679

The GLP-1 part lowers appetite and slows the stomach

Direct head-to-head trials are not yet available, but comparing across studies suggests retatrutide produces approximately 6-10 percentage points more weight loss than tirzepatide at equivalent treatment durations

What Expiration Means for Compounded Semaglutide Unlike FDA-manufactured semaglutide (e.g., brand-name pens), compounded semaglutide typically does not come with a standard expiration date in the same way

With an average weight loss of up to 28.3% over 80 weeks, this triple agonist targets GLP-1, GIP, and GCG receptors, offering possibly more effective outcomes than currently approved medications such as tirzepatide and semaglutide